Literature DB >> 20215880

KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression.

Yanbin Zhou1, Wayne L Hofstetter, Yong He, Wenxian Hu, Abujiang Pataer, Li Wang, Ji Wang, Yihong Zhou, Liping Yu, Bingliang Fang, Stephen G Swisher.   

Abstract

Krüppel-Like Factor 4 (KLF4) functions as a tumor suppressor in some cancers, but its molecular mechanism is not clear. Our recent study also showed that the expression of KLF4 is dramatically reduced in primary lung cancer tissues. To investigate the possible role of KLF4 in lung cancer, we stably transfected KLF4 into cells from lung cancer cell lines H322 and A549 to determine the cells' invasion ability. Our results showed that ectopic expression of KLF4 extensively suppressed lung cancer cell invasion in Matrigel. This effect was independent of KLF4-mediated p21 up-regulation because ectopic expression of p21 had minimal effect on cell invasion. Our analysis of the expression of 12 genes associated with cell invasion in parental, vector-transfected, and KLF4-transfected cells showed that ectopic expression of KLF4 resulted in extensively repressed expression of secreted protein acidic and rich in cysteine (SPARC), an extracellular matrix protein that plays a role in tumor development and metastasis. Knockdown of SPARC expression in H322 and A549 cells led to suppression of cell invasion, comparable to that observed in KLF4-transfected cells. Moreover, retrovirus-mediated restoration of SPARC expression in KLF4-transfected cells abrogated KLF4-induced anti-invasion activity. Together, our results indicate that KLF4 inhibits lung cancer cell invasion by suppressing SPARC gene expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20215880      PMCID: PMC2902679          DOI: 10.4161/cbt.9.7.11106

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  51 in total

1.  Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo.

Authors:  Chad Schultz; Nancy Lemke; Shugang Ge; William A Golembieski; Sandra A Rempel
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

2.  Osteonectin, a bone-specific protein linking mineral to collagen.

Authors:  J D Termine; H K Kleinman; S W Whitson; K M Conn; M L McGarvey; G R Martin
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

3.  Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells.

Authors:  Zhi Y Chen; Jue-Lon Shie; Chi-Chuan Tseng
Journal:  J Biol Chem       Date:  2002-09-23       Impact factor: 5.157

4.  Osteonectin promoter. DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells.

Authors:  M F Young; D M Findlay; P Dominguez; P D Burbelo; C McQuillan; J B Kopp; P G Robey; J D Termine
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

5.  Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model.

Authors:  Jeremy N Rich; Qing Shi; Mark Hjelmeland; Thomas J Cummings; Chien-Tsun Kuan; Darell D Bigner; Christopher M Counter; Xiao-Fan Wang
Journal:  J Biol Chem       Date:  2003-02-17       Impact factor: 5.157

6.  Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung.

Authors:  Fauzia Siddiq; Fazlul H Sarkar; Anil Wali; Harvey Ira Pass; Fulvio Lonardo
Journal:  Lung Cancer       Date:  2004-08       Impact factor: 5.705

7.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Rolf A Brekken; Efthimios Sivridis; Kevin C Gatter; Adrian L Harris; E Helene Sage
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

8.  Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer.

Authors:  Weidong Zhao; Irfan M Hisamuddin; Mandayam O Nandan; Brian A Babbin; Neil E Lamb; Vincent W Yang
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

9.  Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer.

Authors:  Shunsuke Ohnishi; Sumiko Ohnami; Friedrich Laub; Kazunori Aoki; Koichi Suzuki; Yae Kanai; Kazunori Haga; Masahiro Asaka; Francesco Ramirez; Teruhiko Yoshida
Journal:  Biochem Biophys Res Commun       Date:  2003-08-22       Impact factor: 3.575

10.  Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer.

Authors:  Chris Jones; Alan Mackay; Anita Grigoriadis; Antonio Cossu; Jorge S Reis-Filho; Laura Fulford; Tim Dexter; Susan Davies; Karen Bulmer; Emily Ford; Suzanne Parry; Mario Budroni; Giuseppe Palmieri; A Munro Neville; Michael J O'Hare; Sunil R Lakhani
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

View more
  34 in total

Review 1.  Krüppel-like factor 4 (KLF4): What we currently know.

Authors:  Amr M Ghaleb; Vincent W Yang
Journal:  Gene       Date:  2017-02-22       Impact factor: 3.688

2.  Prognostic significance of KLF4 expression in gastric cancer.

Authors:  Isaya Hashimoto; Takuya Nagata; Shinichi Sekine; Makoto Moriyama; Kazuto Shibuya; Shozo Hojo; Koshi Matsui; Isaku Yoshioka; Tomoyuki Okumura; Takashi Hori; Yutaka Shimada; Kazuhiro Tsukada
Journal:  Oncol Lett       Date:  2016-12-14       Impact factor: 2.967

3.  Expression of the tumor suppressor Krüppel-like factor 4 as a prognostic predictor for colon cancer.

Authors:  Nilesh V Patel; Amr M Ghaleb; Mandayam O Nandan; Vincent W Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-10       Impact factor: 4.254

4.  Accumulation of low-dose BIX01294 promotes metastatic potential of U251 glioblastoma cells.

Authors:  Min Young Kim; Shin-Ji Park; Jae Woong Shim; Yu Jin Song; Kwangmo Yang; Seong-Joon Park; Kyu Heo
Journal:  Oncol Lett       Date:  2017-01-19       Impact factor: 2.967

Review 5.  The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.

Authors:  Sharon L I Wong; Maria B Sukkar
Journal:  Br J Pharmacol       Date:  2016-11-25       Impact factor: 8.739

6.  Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells.

Authors:  Guadalupe Villarreal; Ayan Chatterjee; Sarah S Oh; Dong-Jin Oh; Douglas J Rhee
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

7.  Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.

Authors:  Andrea Cercek; Jennifer Wheler; Peter E Murray; Shawn Zhou; Leonard Saltz
Journal:  Invest New Drugs       Date:  2015-08-14       Impact factor: 3.850

8.  Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors.

Authors:  Hyesun Hyun; Joonyoung Park; Kiela Willis; Ji Eun Park; L Tiffany Lyle; Wooin Lee; Yoon Yeo
Journal:  Biomaterials       Date:  2018-07-18       Impact factor: 12.479

Review 9.  Pluripotency transcription factors in lung cancer-a review.

Authors:  Sylwia Sławek; Krzysztof Szmyt; Maciej Fularz; Joanna Dziudzia; Maciej Boruczkowski; Jan Sikora; Mariusz Kaczmarek
Journal:  Tumour Biol       Date:  2015-11-18

10.  The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma.

Authors:  Xin Yin; Yi-Wei Li; Jian-Jun Jin; Yin Zhou; Zheng-Gang Ren; Shuang-Jian Qiu; Bo-Heng Zhang
Journal:  Oncol Lett       Date:  2013-01-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.